allosteric mutant-selective IDH1 inhibitor

oral, in clinical development

from SBDD of prior mIDH inhibitor

J. Med. Chem. 2020, 63, 1612-1623

FORMA Therapeutics, Watertown, MA

FT-2102 (olutasidenib)

FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: